Back to discover
Disease

Epilepsies, Partial

Late-stage therapeutic developmentEmerging researchSteady momentum
MeSHEpilepsies, Partial
4
Publications
10
Clinical trials
1
Related conditions
2022
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
10
All trials
2
Active
9
Late-stage
6
Completed
Late-stage studies

Efficacy and Safety of Zonisamide as a First Add-On Treatment in Focal Epileptic Seizures or Secondary Generalized Tonic-Clonic Seizures: A Clinical Study

Phase 4 · Recruiting · Affiliated Hospital of Nantong University

Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial

Phase 4 · Completed · Mario Negri Institute for Pharmacological Research

Exploratory Open-Label Study of Effects on Responsive Neurostimulator Activity After Intranasal Administration of Single Dose of Valtoco® to People With Epilepsy

Phase 4 · Completed · University of Cincinnati

PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO

Phase 4 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures

Phase 3 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)

Phase 3 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Recently completed

Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial

Phase 4 · Completed · Mario Negri Institute for Pharmacological Research

Exploratory Open-Label Study of Effects on Responsive Neurostimulator Activity After Intranasal Administration of Single Dose of Valtoco® to People With Epilepsy

Phase 4 · Completed · University of Cincinnati

PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO

Phase 4 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures

Phase 3 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)

Phase 3 · Completed · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Phase 3 · Completed · Supernus Pharmaceuticals, Inc.

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20022022
Major themes5
  • Epilepsies, Myoclonic1
  • Epilepsies, Partial1
  • Epilepsy, Absence1
  • Implantable Neurostimulators1
  • Quality of Life1
Leading journals3
  • Neurology2
  • Epilepsia1
  • The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers8
  • Elias WJ2
  • Fountain NB2
  • Gross RE2
  • Salanova V2
  • Sperling MR2
  • Agostini MA1
  • Alexopoulos AV1
  • Anderson WS1
Affiliations (unnormalised)6
  • Aga Khan University1
  • Albert Einstein College of Medicine and Montefiore Medical Center1
  • Austin Health and Royal Children's Hospital1
  • Bambino Gesù Children's Hospital1
  • Department of Clinical Neurosciences1
  • From Indiana University (V.S.1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Epilepsy, Absence2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)

Identifiers
MeSHEpilepsies, Partial
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.